Latest & greatest articles for aids

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aids or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aids and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for aids

501. Albendazole chemotherapy for treatment of diarrhoea in patients with AIDS in Zambia: a randomised double blind controlled trial.

Albendazole chemotherapy for treatment of diarrhoea in patients with AIDS in Zambia: a randomised double blind controlled trial. 8634560 1996 07 05 1996 07 05 2013 11 21 0959-8138 312 7040 1996 May 11 BMJ (Clinical research ed.) BMJ Albendazole chemotherapy for treatment of diarrhoea in patients with AIDS in Zambia: a randomised double blind controlled trial. 1187-91 To determine the value of short course, high dose albendazole chemotherapy in the treatment of persistent diarrhoea related (...) to HIV in unselected patients in urban Zambia. A randomised double blind placebo controlled trial of albendazole 800 mg twice daily for two weeks. Patients were monitored intensively for one month and followed for up to six months. Home care. AIDS services in Lusaka and Ndola. 174 HIV seropositive patients with persistent diarrhoea (defined as loose but not bloody stools three or more times a day for three weeks or longer). No investigations were undertaken except HIV testing after counselling

BMJ1996 Full Text: Link to full Text with Trip Pro

502. The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma.

The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma. 8857005 1997 01 16 1997 01 16 2013 11 21 0028-4793 335 17 1996 Oct 24 The New England journal of medicine N. Engl. J. Med. The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma. 1261-9 Kaposi's sarcoma is the most common cancer in patients with the acquired immunodeficiency syndrome (AIDS). Recently, certain preparations of human chorionic gonadotropin (hCG) have (...) been shown to inhibit the growth of Kaposi's sarcoma cell lines in vitro and in immunodeficient mice. After in vitro evaluation of four commercially available hCG preparations, the most active product was evaluated in 36 patients with AIDS-related Kaposi's sarcoma. In a phase 1-2 trial, 24 patients received intralesional injections of hCG three times a week for two weeks at doses of 250, 500, 1000, or 2000 IU (6 patients each). In each patient three nodular lesions were injected, two with the drug

NEJM1996

503. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.

A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. 8813038 1996 10 22 1996 10 22 2013 11 21 0028-4793 335 15 1996 Oct 10 The New England journal of medicine N. Engl. J. Med. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group (...) of zalcitabine; or 400 mg of didanosine. The primary end point was a > or = 50 percent decline in the CD4 cell count, development of the acquired immunodeficiency syndrome (AIDS), or death. Progression to the primary end point was more frequent with zidovudine alone (32 percent) than with zidovudine plus didanosine (18 percent; relative hazard ratio, 0.50; P<0.001), zidovudine plus zalcitabine (20 percent; relative hazard ratio, 0.54; P<0.001), or didanosine alone (22 percent; relative hazard ratio, 0.61; P

NEJM1996

504. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. 8813039 1996 10 22 1996 10 22 2013 11 21 0028-4793 335 15 1996 Oct 10 The New England journal of medicine N. Engl. J. Med. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per (...) cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. 1091-8 We studied measures of human immunodeficiency virus (HIV) replication, the viral phenotype, and immune function (CD4 cell counts) and the relation of changes in these indicators to clinical outcomes in a subgroup of patients in a controlled trial of early antiretroviral treatment for HIV, the AIDS Clinical Trials Group Study 175. The 391 subjects, each of whom entered the study with a single screening CD4 cell count

NEJM1996

505. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease.

The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. 8943160 1996 12 13 1996 12 13 2015 11 19 0028-4793 335 24 1996 Dec 12 The New England journal of medicine N. Engl. J. Med. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. 1792-8 Transdermal nicotine therapy is widely used to aid smoking cessation, but there is uncertainty about its safety in patients with cardiac disease. In a randomized, double (...) -blind, placebo-controlled trial at 10 Veterans Affairs medical centers, we randomly assigned 584 outpatients (of whom 576 were men) with at least one diagnosis of cardiovascular disease to a 10-week course of transdermal nicotine or placebo as an aid to smoking cessation. The subjects were monitored for a total of 14 weeks for the primary end points of the study (death, myocardial infarction, cardiac arrest, and admission to the hospital due to increased severity of angina, arrhythmia, or congestive

NEJM1996

506. Issues in the development of an AIDS vaccine

Issues in the development of an AIDS vaccine Issues in the development of an AIDS vaccine Issues in the development of an AIDS vaccine Office of Technology Assessment Record Status This is a bibliographic record of a published health technology assessment. The agency responsible for the publication, formerly a member of INAHTA, has subsequently been disbanded. No evaluation of the quality of this assessment has been made for the HTA database. Citation Office of Technology Assessment. Issues (...) in the development of an AIDS vaccine. Washington DC: U. S. Congress. Office of Technology Assessment (OTA) 1995 Authors' objectives The purpose of this background paper is to examine potential adverse reactions to AIDS vaccines in development. In addition, the paper will look at compensation issues and ethical concerns that arise in AIDS vaccine testing and marketing. Project page URL Indexing Status Subject indexing assigned by CRD MeSH AIDS Vaccines; Acquired Immunodeficiency Syndrome; Ethics, Medical; HIV

Health Technology Assessment (HTA) Database.1995

507. How effective is AIDS education? An update

How effective is AIDS education? An update How effective is AIDS education? An update How effective is AIDS education? An update Office of Technology Assessment Record Status This is a bibliographic record of a published health technology assessment. The agency responsible for the publication, formerly a member of INAHTA, has subsequently been disbanded. No evaluation of the quality of this assessment has been made for the HTA database. Citation Office of Technology Assessment. How effective (...) is AIDS education? An update. U. S. Congress. Office of Technology Assessment (OTA). 1995 Authors' objectives To assess what is known about the effectiveness of AIDS education in stopping HIV transmission. The report updates a 1988 OTA Background Paper on the same topic. Authors' conclusions Not yet available. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Acquired Immunodeficiency Syndrome; HIV; Health Education; Preventive Health Services; Preventive Medicine

Health Technology Assessment (HTA) Database.1995

508. Cost and outcome of intensive care for patients with AIDS, Pneumocystis carinii pneumonia, and severe respiratory failure

Cost and outcome of intensive care for patients with AIDS, Pneumocystis carinii pneumonia, and severe respiratory failure Cost and outcome of intensive care for patients with AIDS, Pneumocystis carinii pneumonia, and severe respiratory failure Cost and outcome of intensive care for patients with AIDS, Pneumocystis carinii pneumonia, and severe respiratory failure Wachter R M, Luce J M, Safrin, S, Berrios D C, Charlebois E, Scitovsky A A Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Intensive care for patients with AIDS-related Pneumocystis carinii pneumonia and severe respiratory failure. Type of intervention Treatment Economic study type Cost-effectiveness analysis Study population Patients with AIDS, microbiologically

NHS Economic Evaluation Database.1995

509. Tuberculosis screening among homeless persons with AIDS living in single-room-occupancy hotels

Tuberculosis screening among homeless persons with AIDS living in single-room-occupancy hotels Tuberculosis screening among homeless persons with AIDS living in single-room-occupancy hotels Tuberculosis screening among homeless persons with AIDS living in single-room-occupancy hotels Layton M, Cantwell M, Dorsinville G, Valway S, Onorato M, Frieden T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) Residents of a large single-room-occupancy hotel in Manhattan. The median age of residents was 41 years, (range 27 years to 81 years). 77% were male. 75% were Division of AIDS Services clients, 17% were private tenants, and 8% were full-time room-mates. Setting Community. The economic study was carried out in Manhattan, USA. Dates to which data relate The effectiveness data was derived from a study in October 1992. It was not stated which year the costs refer to. Source of effectiveness data

NHS Economic Evaluation Database.1995

510. Aid to diagnosis of melanoma in primary medical care.

Aid to diagnosis of melanoma in primary medical care. 7888887 1995 04 19 1995 04 19 2013 09 22 0959-8138 310 6978 1995 Feb 25 BMJ (Clinical research ed.) BMJ Aid to diagnosis of melanoma in primary medical care. 492-5 To evaluate an intervention designed to reduce the number of benign melanocytic lesions excised from the skin. A randomised controlled field trial based in the medical practices of two cities. Examination of histopathological reports of 5823 melanocytic skin lesions excised over

BMJ1995 Full Text: Link to full Text with Trip Pro

511. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.

A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. 7854375 1995 03 16 1995 03 16 2015 11 19 0028-4793 332 11 1995 Mar 16 The New England journal of medicine N. Engl. J. Med. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. 693-9 We evaluated the effectiveness of three treatment strategies (...) S A SA Frame P P Powderly W G WG He W W Phillips L L Craven D D van der Horst C C Feinberg J J eng Clinical Trial Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, U.S. Gov't, P.H.S. United States N Engl J Med 0255562 0028-4793 0 Aerosols 673LC5J4LQ Pentamidine 8064-90-2 Trimethoprim, Sulfamethoxazole Drug Combination 8W5C518302 Dapsone AIM IM X ACP J Club. 1995 Sep-Oct;123(2):40-1 N Engl J Med. 1995 Mar 16;332(11):739-40 7854383 AIDS-Related

NEJM1995

512. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.

A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. 7854376 1995 03 16 1995 03 16 2013 11 21 0028-4793 332 11 1995 Mar 16 The New England journal of medicine N. Engl. J. Med. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus (...) infection. NIAID AIDS Clinical Trials Group. 700-5 Cryptococcal meningitis and other serious fungal infections are common complications in patients infected with the human immunodeficiency virus (HIV). Fluconazole is effective for long-term suppression of many fungal infections, but its effectiveness as primary prophylaxis had not been adequately evaluated. We conducted a prospective, randomized trial that compared fluconazole (200 mg per day) with clotrimazole troches (10 mg taken five times daily

NEJM1995

513. Health status and function with zidovudine or zalcitabine as initial therapy for AIDS. A randomized controlled trial. Roche 3300/ACTG 114 Study Group.

Health status and function with zidovudine or zalcitabine as initial therapy for AIDS. A randomized controlled trial. Roche 3300/ACTG 114 Study Group. 7815656 1995 02 09 1995 02 09 2016 10 17 0098-7484 273 4 1995 Jan 25 JAMA JAMA Health status and function with zidovudine or zalcitabine as initial therapy for AIDS. A randomized controlled trial. Roche 3300/ACTG 114 Study Group. 295-301 To evaluate the functional and health status implications of prescribing zalcitabine or zidovudine for initial (...) therapy of acquired immunodeficiency syndrome (AIDS). A substudy of a randomized controlled trial. Private and public clinics and referral centers. Had human immunodeficiency virus (HIV) infection, less than 0.20 x 10(9)/L (200 microliters) CD4+ cells, and either a history of Pneumocystis carinii pneumonia or symptoms of HIV infection. Fifty-eight percent (338/668) of main study enrollees representing 90% of enrollees at participating sites were included in this substudy. Either zalcitabine at 0.75 mg

JAMA1995

514. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group.

A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. 7616988 1995 08 24 1995 08 24 2013 11 21 0028-4793 333 7 1995 Aug 17 The New England journal of medicine N. Engl. J. Med. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. 401-7 (...) was modified so that open-label treatment with 500 mg of zidovudine per day (deferred therapy) was offered when CD4 cell counts fell below 500 per cubic millimeter. The study end points included overall survival, survival free of the acquired immunodeficiency syndrome (AIDS), toxic effects, and changes in CD4 cell counts. There were 1637 subjects who could be evaluated: 547 in the deferred-therapy group, 549 in the group receiving 500 mg of zidovudine immediately, and 541 in the 1500-mg group. The subjects

NEJM1995

515. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group.

Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. 7637721 1995 09 14 1995 09 14 2013 11 21 0028-4793 333 10 1995 Sep 07 The New England journal of medicine N. Engl. J. Med. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. 615-20 Cytomegalovirus retinitis, a sight-threatening infection associated (...) with the acquired immunodeficiency syndrome (AIDS), currently requires lifelong intravenous treatment. An effective oral treatment would be an important advance. We compared oral with intravenous ganciclovir in an open-label, randomized study in patients with AIDS and newly diagnosed, stable cytomegalovirus retinitis (the disease was stabilized by three weeks of treatment with intravenous ganciclovir). Sixty subjects were randomly assigned to maintenance therapy with intravenous ganciclovir at a dose of 5 mg per kilogram of body weight

NEJM1995

516. National AIDS programme managers, report on the eighth intercountry meeting, Amman, Jordan, 10-13 April 1995

National AIDS programme managers, report on the eighth intercountry meeting, Amman, Jordan, 10-13 April 1995 WHO IRIS: National AIDS programme managers, report on the eighth intercountry meeting, Amman, Jordan, 10-13 April 1995 Browse Related links Files in This Item: File Description Size Format 10.34 MB Adobe PDF Title: National AIDS programme managers, report on the eighth intercountry meeting, Amman, Jordan, 10-13 April 1995 Authors: Issue Date: 1995 Publisher: World Health Organization

WHO1995

517. Report on the workshop on the role of media in AIDS prevention and control, Islamabad, Pakistan, 28-30 November 1994

Report on the workshop on the role of media in AIDS prevention and control, Islamabad, Pakistan, 28-30 November 1994 WHO IRIS: Report on the workshop on the role of media in AIDS prevention and control, Islamabad, Pakistan, 28-30 November 1994 Browse Related links Files in This Item: File Description Size Format 469.13 kB Adobe PDF Title: Report on the workshop on the role of media in AIDS prevention and control, Islamabad, Pakistan, 28-30 November 1994 Authors: Issue Date: 1995 Publisher

WHO1995

518. Risk, knowledge and behaviour: HIV/AIDS education programmes and young people

Risk, knowledge and behaviour: HIV/AIDS education programmes and young people Risk, knowledge and behaviour: HIV/AIDS education programmes and young people Risk, knowledge and behaviour: HIV/AIDS education programmes and young people Oakley A, Fullerton D Authors' objectives The authors had 3 main objectives: (1) to examine the methodologies and findings of research relevant to HIV or AIDS knowledge with particular relevance to young people in the North East Thames Region of the UK; (2 (...) ) to examine the impact of different intervention programmes on knowledge of risk and on behavioural outcomes; and (3) to make recommendations as to the most effective HIV or AIDS education strategies for future implementation within the North East Thames Region of the UK. Searching Social Science Citation Index on BIDS, MEDLINE, PsycLIT, ERIC, the Health Education Authority's Unicorn database (internal library management system) and the National HIV/AIDS Prevention Information Service database were

DARE.1994

519. Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/micro1iters in 5 European countries

Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/micro1iters in 5 European countries Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/micro1iters in 5 European countries Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/micro1iters in 5 European countries Simpson K (...) , Hatziandreu E J, Andersson F, Shakespeare A, Oleksy I, Tosteson A N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Antiviral treatment with Zalcitabine plus Zidovudine for AIDS. Type of intervention Treatment. Economic study type Cost

NHS Economic Evaluation Database.1994

520. Megestrol acetate in patients with AIDS and cachexia.

Megestrol acetate in patients with AIDS and cachexia. Megestrol acetate in patients wit... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1994 ) Volume: 121 , Issue: 6 , Pages: 400-408 PubMed: Available from or Find this paper at: Abstract OBJECTIVE: To study the effects of a megestrol acetate liquid formulation (800 mg/d) on body weight, body composition, caloric intake, and mental (...) outlook in patients with the acquired immunodeficiency syndrome (AIDS) who had cachexia. DESIGN: Twelve-week, multicenter, randomized, double-blind, placebo-controlled trial. SETTING: Multiple clinical centers. PATIENTS: 100 patients with AIDS who had weight loss of 10% or more of ideal body weight were randomly assigned to placebo (n = 48) or megestrol acetate (n = 52). MEASUREMENTS: Caloric intake, body weight, body composition, and sense of well-being. RESULTS: Most patients receiving megestrol

Annals of Internal Medicine1994